Company intelligence / Profile preview

Taiho Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Taiho has successfully developed and commercialized several anticancer drugs including Futraful, UFT, TS-1, LONSURF, and LYTGOBI. LONSURF received FDA approval in 2015 and European Commission approval in 2016. LYTGOBI (futibatinib) received accelerated approval in the US in 2022, followed by approval in Japan and Europe in 2023.

Therapeutic areas: Rare DiseasesMen's HealthImmunologyOncology
Modalities: Small moleculesoral anticancer drugs
Industry: Pharma

Drug pipeline

44 assets

trifluridine

Approved

43 more assets in the full pipeline.

Partnerships

Nichiban Co., Ltd.Kotai Kasei Co., Ltd.

Beyond the preview

Go deeper on Taiho Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiho Pharmaceutical Co., Ltd..